FDA has granted orphan drug status to MT-601, which is being developed by Marker Therapeutics. The drug is intended to treat people with pancreatic cancer and contains multiple tumor antigens. Drugs with this status can receive grants from the FDA to cover the costs of clinical trials, tax credits and seven years of market exclusivity in the U.S. after approval.